Bayer Stock Breaks Above a Key Technical Level as Investors Weigh Supreme Court Verdict Against Pipeline Progress

Bayer's stock breaches the 200-day moving average, signaling potential sentiment shift, as investors weigh strong operational results against upcoming US Supreme Court ruling on Roundup liability.

The shares of Bayer crossed the 200-day moving average last week, closing at €36.16, a modest but technically significant move that signals a potential shift in sentiment. That line, sitting at roughly €35.80, had acted as resistance for weeks — and its breach gives chart-watchers reason to look for the next hurdle at the 50-day average of €38.39. Yet the stock’s year-to-date loss of roughly six per cent tells a fuller story: the market remains deeply divided between an improving operating picture and the legal albatross still hanging over the company.

At the heart of that divide is the Durnell case, now before the US Supreme Court. The justices are examining whether federal law pre-empts state verdicts against Bayer over glyphosate warning labels, given the EPA’s own safety assessment. A ruling in Bayer’s favour would gut the bulk of the roughly 65,000 outstanding Roundup claims; a loss would keep the litigation wave rolling. Legal observers expect a decision as soon as this month. Meanwhile, a separate multibillion-dollar Roundup settlement — costing Bayer as much as US$7.25 billion — saw its opt-out period close on 4 June, with court approval expected in July. The company has financed the deal through an US$8 billion bank credit line, importantly avoiding a dilutive capital increase that had worried shareholders.

Behind the legal noise, the operational engines are humming. Bayer reported first-quarter 2026 revenue of €13.41 billion, a currency-adjusted increase of 4.1 per cent, while operating profit reached nearly €4.5 billion. Adjusted earnings per share of €2.71 came in ahead of expectations, lifted by the pharma division where products such as Nubeqa and Kerendia are compensating for older patent expiries. The pipeline adds further momentum: the FDA has granted accelerated review for Asundexian, one of five potential blockbusters. On the renal front, fresh Phase III data from the FIND-CKD study, presented at the 63rd ERA Congress, demonstrated that Finerenon significantly slows kidney function decline in patients with non-diabetic chronic kidney disease — an expansion of its therapeutic reach that analysts say broadens the drug’s market potential.

A less-heralded growth driver sits in agriculture. Bayer’s “Climate Fieldview” platform, billed as the world’s largest digital farming service, aggregates machine, soil, satellite and weather data to generate planting recommendations. The company claims users see an 8 per cent yield improvement per hectare. Trading at an EV/Ebitda multiple of roughly 8, the stock carries a steep discount compared with pure-play agri-tech rivals — a gap that some market observers believe could narrow if the digital business continues to scale.

UBS is among those seeing value, reiterating a buy rating with a €52 price target. For now, however, the shares remain trapped between a strong operational base and a judiciary calendar that will decide whether the path forward is cleared or crowded. The 200-day line has been crossed, but the real verdict — from Washington — is still to come.